To search for a gene(s) conferring susceptibility to diabetic nephropathy (DN), we genotyped over 80,000 genebased single nucleotide polymorphisms (SNPs) in Japanese patients and identified that the engulfment and cell motility 1 gene (ELMO1) was a likely candidate for conferring susceptibility to DN, in view of the significant association of an SNP in this gene with the disease (intron 18؉9170, GG vs. GA؉AA, 2 ‫؍‬ 19.9, P ‫؍‬ 0.000008; odds ratio 2.67, 95% CI 1.71-4.16). In situ hybridization (ISH) using the kidney of normal and diabetic mice revealed that ELMO1 expression was weakly detectable mainly in tubular and glomerular epithelial cells in normal mouse kidney and was clearly elevated in the kidney of diabetic mice. Subsequent in vitro analysis revealed that ELMO1 expression was elevated in cells cultured under high glucose conditions (25 mmol/l) compared with cells cultured under normal glucose conditions (5.5 mmol/l). Furthermore, we identified that the expression of extracellular matrix protein genes, such as type 1 collagen and fibronectin, were increased in cells that overexpress ELMO1, whereas the expression of matrix metalloproteinases was decreased. These results indicate that ELMO1 is a novel candidate gene that both confers susceptibility to DN and plays an important role in the development and progression of this disease. Diabetes 54:1171-1178, 2005
D
iabetic nephropathy (DN) is the leading cause of end-stage renal disease in Western countries and Japan (1, 2) . The pathogenesis of DN appears to be multifactorial. Several genetic and environmental factors are likely to contribute to its development and progression, although the precise mechanisms for this contribution are unknown. Because cumulative epidemiological findings have provided evidence that genetic susceptibility plays an important role in the pathogenesis of this renal disease (3, 4) , there have been extensive efforts to identify the gene(s) involved in the development and progression of nephropathy, in both type 1 and type 2 diabetes (5,6), but no definitive results have yet emerged.
Single nucleotide polymorphisms (SNPs) are the most common genetic variation and are considered to be potentially useful as markers to identify genetic variants that may confer susceptibility to common etiologically complex diseases.
After developing a high-throughput system for genotyping SNPs that combines the Invader assay with multiplex PCRs (7), we carried out genome-wide association studies using SNPs to identify loci involved in susceptibility to common diseases.
In the study reported here, we performed a genomewide SNP genotyping analysis of a large panel of Japanese patients with type 2 diabetes in an effort to identify the gene(s) conferring susceptibility to DN. Our data suggest that the engulfment and cell motility 1 gene (ELMO1) is likely to contribute to genetic susceptibility to DN. selected from our gene-based Japanese SNP database (available at http:// snp.ims.u-tokyo.ac.jp) (8, 9) . The genotype of each SNP locus was analyzed with Invader assays, as previously described (7) .
Our first screening involved genotyping 94 DN patients (63 men and 31 women, age 57.9 Ϯ 12.5 years, duration of diabetes 18.6 Ϯ 9.7 years, HbA 1c 7.7 Ϯ 1.3%, mean Ϯ SD) and 94 control patients (37 men and 57 women, age 62.7 Ϯ 9.9 years, duration of diabetes 16.2 Ϯ 8.4 years, HbA 1c 7.4 Ϯ 1.1%) for 81,315 SNP loci. By evaluating the statistical data using 2 ϫ 3 or 2 ϫ 2 contingency tables, we selected SNPs that showed significant differences in genotypic or allelic frequencies between the DN and control groups. Then we analyzed the SNPs in a larger number of subjects-466 DN and 266 control patients (DN patients: 305 men and161 women, age 59.6 Ϯ 13.5 years, duration of diabetes 17.3 Ϯ 10.4 years, HbA 1c 7.8 Ϯ 1.1%; control patients: 125 men and 141 women, age 62.9 Ϯ 12.0 years, duration of diabetes 14.6 Ϯ 9.3 years, HbA 1c 7.1 Ϯ 1.2%) (10) . The ethics committees of the Institute of Physical and Chemical Research and each participating institution approved the study protocol. Identification of polymorphisms in ELMO1 and genotyping. PCR primers were designed using GenBank ELMO1 sequence data (accession nos: AC078843, AC083861, AC007444, AC009196, AC078844, and AC007349) to amplify specific regions of ELMO1. Repetitive elements were excluded from the search by invoking the Repeat Masker computer program (available at http://www.repeatmasker.org) in the manner described by Bedell et al. (11) . PCR experiments and DNA sequencing were carried out as previously described (12) . Genotyping of each SNP in the critical region was performed with the Invader assay or, in some cases, by the TaqMan assay using maximum number of the subjects.
ISH.
Tissue preparation. Under pentobarbitol anesthesia, the 30-week-old mice were flushed with PBS through the abdominal aorta followed by perfusion Genotype data are number of subjects (%).
ELMO1 AND DIABETIC NEPHROPATHY
with 4% paraformaldehyde buffered with 0.1 mol/l PBS (pH 7.4). The kidneys were swiftly removed and cut into small pieces. The renal cortex tissue was immediately dissected and immersed into a fresh portion of the same fixative at 4°C overnight. All steps were carried out with care to avoid contamination with RNase. Diethylpyrocarbonate-treated water was used at 0.1% to prepare each buffer. Fixed samples were thoroughly rinsed with 0.1 mol/l PBS (pH 7.4), subsequently dehydrated by passage through an alcohol series, and cleared in xylene. ISH was performed on paraffin-embedded sections. ISH study. Antisense and sense single-strand cRNAs were synthesized from cDNA fragments encoding ELMO1 or encoding ELMO2 using RT-PCR. The ELMO1 cDNA fragment consisted of 525 bp (mouse sequence nucleotides 51-575, GenBank accession no. AY406934). The ELMO2 cDNA fragment consisted of 501 bp (mouse sequence nucleotides 51-551, GenBank accession no. AF398884). Each fragment was subcloned into pCRII-TOPO vector (Invitrogen, Carlsbad, CA). The template of ELMO1 subunit was linearized with the restriction enzyme HindIII, and the labeled RNA probe was synthesized with T7 RNA polymerase in the presence of digoxigenin (DIG)-labeled UTP (DIG Labeling Kit; Roche Diagnostics, Basel, Switzerland) for antisense-probe, or it was linearized with the restriction enzyme EcoRV, and the labeled RNA probe was synthesized with SP6 RNA polymerase for sense-probe. The template of ELMO2 subunit was linearized with the restriction enzyme EcoRV, and the labeled RNA probe was synthesized with SP6 RNA polymerase for antisense-probe, or the template of ELMO2 subunit was linearized with the restriction enzyme HindIII, and labeled RNA probe was synthesized with T7 RNA polymerase for sense-probe. The probes were precipitated and DIG incorporation was assessed by dot blotting. After dewaxing, the tissue sections were dipped into 0.01 mol/l citrate buffer (pH6.0) at 95°C for 30 min, rinsed with 0.1 mol/l PBS (pH 7.4), and permeabilized with 2.5 g/ml proteinase K (Roche Diagnostics) at 37°C for 10 min. Next, they were briefly washed with 0.1 mol/l PBS, rinsed in 0.1 mol/l triethanolamine (pH 8.0), and then acetylated with 0.1 mol/l triethanolamine containing 0.25% acetic anhydride for 10 min. Hybridization was conducted by the method described previously (13) . Briefly, sections were prehybridized and then hybridized with 500 ng/ml DIG-labeled antisense or sense cRNA probe for 17 h at 50°C in a hybridization buffer containing 50% deionized formamide, 1 ϫ Denhardt's solution, 10% dextran sulfate, 600 mmol/l NaCl, 0.025% SDS, 5 mmol/l EDTA (pH 8.0), 0.25 mg/ml yeast tRNA, and 10 mmol/l Tris-HCl (pH 7.6). During hybridization, the slides were covered with parafilm and kept in a closed, moist chamber. After hybridization, the samples were rinsed three times with 5 ϫ sodium chloride-sodium citrate (SSC) for 10 min at 50°C. The samples were stringently washed with 2 ϫ SSC containing 50% formamid for 20 min at 50°C and thoroughly washed twice with 0.2 ϫ SSC for 20 min at 50°C. Then the samples were immersed in 1.5% blocking reagent dissolved in DIG buffer 1 (100 mmol/l Tris-HCl, pH 7.5, containing 150 mmol/l NaCl) for 60 min at room temperature, preincubated in normal rabbit serum at a dilution of 1:500 in DIG buffer 1 for 30 min, and subsequently incubated in anti-DIG sheep polyclonal antibodies at a dilution of 1:1,000 in DIG buffer 1 for 30 min at room temperature and rinsed with DIG buffer 1. These samples were then incubated in biotinylated anti-sheep rabbit polyclonal antibodies at a dilution of 1:1,000 in DIG buffer 1 for 30 min at room temperature and rinsed again with DIG buffer 1. The samples were next treated with avidin-biotinylated horseradish peroxidase complex solution (Vector Laboratories, Burlingame, CA) at room temperature for 60 min. After immunological incubation, the samples were extensively washed with DIG buffer 1, then processed using 0.1% 3,3Ј-diaminobenzidine hydrochloride substrate dissolved in 50 mmol/l Tris-HCl (pH 7.4) containing 0.05% H 2 O 2 for 5 min at room temperature in the dark and examined for expression of the specific gene of interest. After a brownish color developed, the reaction was stopped by rinsing in Tris-EDTA buffer (10 mmol/l Tris-HCl, pH 7.6, containing 1 mmol/l EDTA), and the target mRNA signals were visualized. The sections were counterstained with periodic acid-Shiff reagent, dehydrated, and finally mounted in Entellan new (Merck). Photomicrographic evaluation. The slides were examined under brightfield microscope Optiphoto-equipped Coolpix digital camera system (Nikon), with particular attention paid to evaluation of the glomerular cross views. Real-time quantitative RT-PCR. Total RNA was prepared from COS cells cultured under normal (5.5 mmol/l) or high (25 mmol/l) glucose conditions. Quantitative real-time PCR was performed using the primers described below. For ELMO1: sense 5Ј-CCG GAT TGT GCT TGA GAA CA-3Ј, antisense 5Ј-CTC ACT AGG CAA CTC GCC CA-3Ј; fibronectin: sense 5Ј-GCT CAG AAT CCA AGC GGA GA-3Ј, antisense 5Ј-CTT TCC CAA GCA ATT TTG ATG G-3Ј; for collagen I (␣1): sense 5Ј-CAC CAA TCA CCT GCG TAC AGA-3Ј, antisense 5Ј-TCA CAG ATC ACG TCA TCG CAC-3Ј; for transforming growth factor (TGF)-␤1: sense 5Ј-AGG TCA CCC GCG TGC TAA T-3Ј, antisense 5Ј-GGT TCA GGT ACC GCT TC TCG -3Ј; for matrix metalloproteinase (MMP)-2: sense 5Ј-GAT GCC GCC TTT AAC TGG AG-3Ј, antisense 5Ј-CAT CTG CGA TGA GCT TGG G-3Ј; for MMP3: sense 5Ј-TTT CTC GTT GCT GCT CAT GAA-3Ј, antisense 5Ј-GAG ACA GGC GGA ACC GAG T-3Ј; and for GAPDH: sense 5Ј-GCT CAG AAT CCA AGC GGA GA-3Ј, antisense 5Ј-CTT TCC CAA GCA ATT TTG ATG G-3Ј. The amplifications were carried out in a 25-l reaction volume containing 1 ϫ EX Taq buffer, 200 nmol/l dNTPs, 1/20,000 SYBR Green, 800 nmol/l of each primer, 0.05 units EX TaqDNA polymerase, 2.75 ng TaqStart antibody (Clontech), and 5 ng of template. The thermal profile used was 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 63°C for 30 s, and 72°C for 30 s. The amplification and quantification was performed in an ABI PRISM 7000 Sequence Detection System (PE Applied Biosystems) and normalized to GAPDH. Statistical analysis. Statistical analyses for the association study, haplotype frequencies, and calculation of linkage disequilibrium (LD) coefficients (DЈ or ⌬) were described previously (14) . Analysis of haplotype structure was carried out by estimating haplotype phasing using an expectation maximization algorithm (15) and by constructing haplotype blocks as previously described (10, 16) . For quantitative RT-PCR experiments, comparisons among three or more groups were analyzed by one-way ANOVA, followed by Scheffe's tests to evaluate statistical differences between two groups.
RESULTS
Genome-wide association study. Among the 81,315 SNP loci we tested in our original screening, 1,615 SNP loci had significant P values Ͻ0.01 between DN and control patients (see supplementary Genotype data are presented as number of subjects (%). *Landmark SNP used for the genome-wide screening.
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testing error was made using the following calculation:
Overall P values (P1st ϫ P2nd) ϫ number of tests (1st ϩ 2nd) ϭ 0.001 ϫ 0.00005 ϫ (81,315 ϫ 4 ϩ 1,615 ϫ 4) ϭ 0.017. After performing this correction, we concluded that the association of this landmark SNP with DN was statistically significant. Subsequent mapping of LD around the landmark SNP in ELMO1 revealed that LD in this region extended ϳ100 kb upstream and 100 kb downstream of the landmark site (Fig. 1) . Therefore, the critical region for susceptibility to DN seemed likely to lie within this 200-kb high-LD block. Because ELMO1 is the only gene within this LD block, it was concluded that ELMO1 was the most likely candidate for conferring susceptibility to DN.
We next screened for additional polymorphisms in ELMO1 and identified another 516 polymorphisms (448 SNPs, 49 insertion/deletion polymorphisms, 18 tandem repeat polymorphisms, and 1 other polymorphism) (see supplementary Fig. 1 in the online appendix) . Genotyping of these variations using the maximum number of DN (n ϭ 640) and control (n ϭ 426) subjects showed that several of them were associated with DN (Tables 2 and 3 ; information on those SNPs can be found in supplementary Table 2 in the online appendix); in particular, SNP in intron 18 (ϩ9170 A/G) had the strongest association with DN (GG vs. AGϩAA, 2 ϭ 19.9, P ϭ 0.000008; OR 2.67, 95% CI 1.71-4.16). We also analyzed haplotype structure using the expectation maximization algorithm and found that nine SNPs in ELMO1, with an allelic frequency of Ͼ0.15, constituted one haplotype block, and that the five common haplotypes accounted for Ͼ90% of the population (Fig. 2) . Subsequent association studies with DN for each haplo- type identified a significant association of haplotypes 2 and 6 with DN. However, the association of these haplotypes was not stronger than that found at the ϩ9,170 A/G locus.
ISH.
To identify a possible role of ELMO1 in the pathogenesis of DN, we examined the expression pattern of this gene in normal (db/ϩm) and diabetic (db/db) mouse kidney by ISH and identified that the expression of ELMO1 could be observed mainly in glomerular epithelial cells and tubular epithelial cells (Fig. 3) . The signal of ELMO1 mRNA was remarkably increased in the kidney of diabetic mice (db/db 30 weeks old) ( Fig. 3E and F) compared with that of controls (db/ϩm 30 weeks, Fig. 3B and C) , whereas the expression of ELMO2 was not different between these mice (Fig. 3H, I , K, and L). We also examined ELMO1 expression by RT-PCR in various kinds of cultured cells, including glomerular mesangial cells, proximal tubular epithelial cells, COS cells, and retinal pigment epithelial cells, and could only detect definite expression in COS cells.
Real-time quantitative RT-PCR for ELMO1.
We next examined the effects of glucose on the expression of ELMO1 in COS cells cultured under either normal (5.5 mmol/l) or high (25 mmol/l) concentrations of glucose. As shown in Fig. 4 , the expressions of ELMO1 were significantly increased in the cells cultured under high glucose conditions compared with those in the cells under normal conditions or conditions in which osmolarity had been adjusted with mannitol (ϩ19.5 mmol/l). These results suggested that the increase in ELMO1 expression under high glucose conditions might contribute to the development and progression of DN. Expression of extracellular matrix genes in ELMO1-overexpressing cells. From the results described above, it was suggested that the excess expression of ELMO1 under high glucose conditions might contribute to the development and progression of DN. Although the precise mechanism of the development and progression of DN is still unknown, it has been suggested that TGF-␤1-induced overaccumulation of extracellular matrix proteins is, at least in part, involved in the pathogenesis of DN (17).
Therefore, we investigated the effects of excess expression of ELMO1 on the expression of extracellular matrix protein genes, as well as on that of the TGF-␤1 gene, using cells that overexpressed ELMO1. As shown in Fig. 5 , the expression of these genes in cells stably transfected with pcDNA3.1-ELMO1 were remarkably increased compared with those in the cells transfected with pcDNA3.1-LacZ (TGF-␤1 1.36-fold vs. 1.5-fold; collagen type 1 [␣1] 5.5-fold vs. 5.8-fold; fibronectin 11.1-fold vs. 12.1-fold; ELMO1-line 1 and ELMO1-line 2 vs. LacZ, respectively) ( Fig. 5B-D) , whereas the expression of MMPs were reduced (MMP2 0.66 vs. 0.27 and MMP3 0.54 vs. 0.57; ELMO1-line 1 and ELMO1-line 2 vs. LacZ, respectively) ( Fig. 5E and F) .
DISCUSSION
In a genome-wide case-control association study using SNPs as genetic markers, we identified ELMO1 as a candidate gene conferring susceptibility to DN. Our data also suggest that one intronic SNP (intron 18ϩ9170) might affect susceptibility to DN. The results presented here, as well as in recent publications (10, 18, 19) , provide evidence that a genome-wide case-control association study using gene-based SNPs as genetic markers is a powerful strategy for identifying genes associated with susceptibility to common diseases. Epidemiological findings had strongly suggested a contribution of genetic factors to the development and progression of DN (3,4), but worldwide efforts have so far failed to identify any solid evidence to indicate a genetic susceptibly to the disease. In many cases, the results were conflicting, probably because sample sizes were often inappropriate. However, the major cause of failures to obtain solid conclusions is possibly that multiple genetic factors are involved in DN in a complex manner and the influence of each individual factor is too weak to be identified. Therefore, approaches other than standard candidate-gene analysis or family-based linkage analysis are required to identify genes that are involved in susceptibility to common diseases such as DN. As we began this study by analyzing a huge number of loci (81,315 SNPs) on a genome-wide basis, using a high-throughput genotyping system developed in our institute, and because all of the SNPs contributing to this report are the gene-based SNPs from the Japanese population (8,9), we were able to screen for candidate genes for disease susceptibility more efficiently than would be possible using other SNP databases.
The ELMO1 gene, on chromosome 7p14, is a known mammalian homologue of the C. elegans gene, ced-12, which is required for engulfment of dying cells and for cell migration (20) . ELMO1 has also been reported to cooperate with CrkII and Dock180, which are homologues of C. elegans ced-2 and ced-5, respectively, to promote phagocytosis and cell shape changes (20, 21) . However, until now no evidence has been reported to suggest a role for this gene in the pathogenesis of DN.
In this study, we showed that the expression of ELMO1 was increased in the kidney of diabetic mice compared with that of control mice, whereas the expression of ELMO2 was not different between diabetic and nondiabetic mice. We also identified that the increased expression of ELMO1 could be observed in the glomeruli isolated from diabetic mice by real-time quantitative PCR (data not shown). These results suggested some role of ELMO1 in the pathogenesis of DN.
We next examined the effects of glucose concentrations on the expression of this gene in COS cells, and we found that the expression of ELMO1 was significantly elevated in cells under high glucose conditions compared with cells under normal glucose conditions. The effect of glucose on the expression of ELMO1 was not due to increased osmolality, because the expression was not elevated in cells under normal glucose conditions with 19.5 mmol/l mannitol. From these observations, we speculated that increases in the expression of ELMO1 under high glucose conditions might contribute to the development and progression of DN. Interestingly, the excess expression of ELMO1 resulted in increased expression of extracellular matrix genes and in the decreased expression of MMP genes. Therefore, it is suggested that persistent excess of ELMO1 leads to the overaccumulation of extracellular matrix proteins and to the development and progression of diabetic glomerulosclerosis. Because the increase in the expression of extracellular matrix genes is much greater than that of TGF-␤1, a TGF-␤1-independent mechanism was thought to exist.
The precise mechanism of ELMO1 influence on the expression of these genes is still unknown. Previous reports suggested that ELMO1 cooperates with Dock180 to function as an activator for Rac-1 (21) . Accordingly, we next examined the effects of Rac-1 and coexpression of Dock180 with ELMO1 on the expression of both extracellular matrix genes and MMPs. However, no significant additional effect of these factors on the expression of these genes was detected (data not shown), suggesting that the effects of ELMO1 on the regulation of expression of these genes were independent of Rac-1.
The mechanism whereby ELMO1 polymorphisms affect the susceptibility to DN also requires further examination. ELMO1 is Ͼ500 kb, and the polymorphisms associated with DN are located far from the transcription start site. Because we could not identify any variations within the coding region or splicing area, we thought that the identified variations might in fact affect ELMO1 gene expression under a high glucose milieu. Indeed, several modulators for transcriptional activity were reported to be located as far as hundreds of kilobasepairs from the transcription initiation site. We then searched for specific protein binding to the DNA corresponding to several candidate regions within ELMO1 and identified high glucose-induced specific protein binding at the landmark SNP site (data not shown). Because the sequence including this landmark SNP site (intron 18ϩ1970) was compatible with the binding site for GCR-1 (see supplementary Table 2 in the online appendix), which could control the transcriptional activity of glycolytic enzyme genes in response to the alteration of extracellular concentrations of glucose in Saccharomyces cerevisiae (22) , this region might be directly involved in conferring susceptibility to DN. However, the elucidation of the precise mechanism requires further study.
In summary, we identified ELMO1 as a candidate gene for conferring susceptibility to DN based on results from a genome-wide case-control association study using genebased SNPs. The evidence presented here suggests that ELMO1 could be a useful target for new drugs to aid in the prevention and treatment of DN.
